Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli

J. F. Fisher, M. J. Carter, J. Parsons, J. P. Rissing

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Moxalactam (LY127935; 6059S), a new broad-spectrum β-lactam antibiotic, was used successfully with an aminoglycoside in a patient with Serratia marcescens meningitis complicating a neurosurgical procedure. With a bioassay method, peak and trough serum and cerebrospinal fluid concentrations of moxalactam were determined during therapy. Mean peak and trough serum levels wer 100.6 and 35.5 μg/ml, respectively. corresponding mean peak and trough cerebrospinal fluid levels were 12.4 and 10.38 μ Cerebrospinal fluid levels of moxalactam exceeded the minimal bactericidal concentration for the infecting organism by more than 30-fold throughout therapy. No untoward effects of moxalactam were observed. Moxalactam may be useful agent in the treatment of meningitis due to susceptible gram-negative bacilli.

Original languageEnglish (US)
Pages (from-to)218-221
Number of pages4
JournalAntimicrobial agents and chemotherapy
Issue number2
StatePublished - 1981

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli'. Together they form a unique fingerprint.

Cite this